Behind the Microscope: Exploring early detection research скачать в хорошем качестве

Behind the Microscope: Exploring early detection research

Detecting ovarian cancer early is a complex challenge, but one that 73% of community members say needs to be a priority. Research like this hasn’t been possible before, but today, science has advanced far enough for us to invest in early detection research and know that we’ll make tangible progress for women facing this disease. The mDETECT blood test identifies changes to DNA caused by ovarian cancer using a special sequencing technique. Currently, the CA125 blood test is used in the process to diagnose ovarian cancer in Canada. This test looks at a protein called “cancer antigen 125” (CA125), however it isn’t always reliable. Women can have high levels of the CA125 protein for a variety of reasons not related to ovarian cancer and not all women with ovarian cancer will have increased levels of it. This is where the mDETECT blood test stands out. Because of the special DNA sequencing technique that mDETECT uses, it can be more sensitive than the CA125 test. “Our early results show that we’re much better at identifying ovarian cancer than the CA125 blood test,” says Dr. Mueller. “Our mDETECT blood test may better distinguish between cancer and non-cancerous conditions, reducing false positives and false negatives. With this investment we will now study if our test can actually help women facing ovarian cancer.”